MedTrace Logo

Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)

NCT06534723 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 570

Last updated 2025-12-29

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimer's dementia

Conditions

  • Alzheimer's Dementia

Interventions

DRUG

Wujia Yizhi granules

Drug: Wujia Yizhi granuless

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Sichuan Jishengtang Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiaochun Chen, Medical Doctor · Fujian Medical University Affiliated Union Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-20
Primary Completion
2026-08-31
Completion
2026-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06534723 on ClinicalTrials.gov